We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




New Cartilage Implant Treats Osteoarthritis of the Big Toe

By HospiMedica International staff writers
Posted on 20 Jul 2016
Print article
Image: The Cartiva Synthetic Cartilage Implant (SCI) (Photo courtesy of Cartiva).
Image: The Cartiva Synthetic Cartilage Implant (SCI) (Photo courtesy of Cartiva).
A novel biomedical polymer implant mimics the physical characteristics of articular cartilage, relieving pain while maintaining joint function.

The Cartiva Synthetic Cartilage Implant (SCI) is intended for use in the treatment of patients with painful arthritis at the base of the great toe as an alternative to fusion, providing pain relief and improvement in both function and motion by replacing damaged cartilage. Made of an organic polymer-based biomaterial comprised of 40% polyvinyl alcohol (PVA) and saline, the cylindrical synthetic polymer provides cartilage-like compressible, low-friction, and a durable bearing surface.

The SCI is placed in a single surgical procedure, addressing focal articular defects. Due to the similar osmotic, physical, and frictional properties of Cartiva SCI to native cartilage, joint-resurfacing repairs using this implant does not require replacement of the opposing articular surface. Consequently, the procedure does not require significant removal of healthy tissue, resulting in nominal surgical trauma and rapid recovery. The procedure takes about 35 minutes and, unlike fusion, allows the patient to immediately bear weight.

A randomized, multicenter, 236-patient clinical trial that compared outcomes from patients who received the SCI with patients who underwent fusion showed that the SCI group posted a 93% reduction in median pain and a 168% improvement in median function in sporting activities, and a 65% improvement in daily living activities. SCI patients also had a 26% increased range of movement from baseline. The Cartiva SCI is a product of Cartiva (Alpharetta, GA, USA), and has been approved by the U.S. Food and Drug Administration (FDA).

“Before Cartiva SCI, the options we could provide to patients with osteoarthritis of the great toe were limited, as the fusion procedure often necessitates sacrificing range of motion to get pain relief,” said Mark Glazebrook, MD, of the Queen Elizabeth II Health Sciences Centre (Halifax, Canada). “Due to the simplicity of the procedure, speed of recovery and range of motion benefits, I see that patients are relieved to have this option available to them, and the majority are electing Cartiva over fusion.”

PVA is derived from polyvinyl acetate through partial or full hydroxylation. Depending on the degree of polymerization and hydrolysis, the physical characteristics, chemical properties, and mechanical properties of PVA can be customized to defined functional requirements. Properties can be further modified by crosslinking, which results in a material that can be swollen to produce a hydrogel. PVA’s properties also make it a good replacement for cartilage, which is typically comprised of 60-80% water, with a mass balance primarily of collagen.

Related Links:
Cartiva


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
LED Phototherapy System
Bililed Mini+

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.